CHRONIC BRAIN ISCHEMIA. CURRENT STATE OF THE PROBLEM

Abstract

In the Russian literature the term dyscirculatory encephalopathy is most commonly used for designation of the chronic brain ischemia. The therapy of dyscirculatory encephalopathy is a problem that is far from resolution. The major modes of DE pathogenetic therapy are use of antiplatelet agents, vasoactive agents, agents of neurometabolic action. The Vinpocetine drug has pleurotropic action, including vasoactive, antiplatelet, antithrombogenic and neurometabolic effects. More than 100 experimental and clinical studies with use of more than 30 000 patients were conducted that demonstrated its high clinical effectiveness. Authors performed an observation study of Vinpocetine effectiveness in 124 patients with DE of Stage I, II and III aged from 40 to 55 years. The dynamics of subjective and objective neurologic symptoms, cognitive values (MMSE, MoCa, watch drawing test, 10 words memorizing test) was assessed, speed of simple visual and motor reaction was evaluated. The study results demonstrated high effectiveness of complex therapy with use of Vinpocetine with respect to cognitive disturbances, major neurologic syndromes and functional possibilities of the brain in conditions of chronic ischemia in DE patients of middle age.

Keywords

• chronic brain ischemia
• treatment of dyscirculatory encephalopathy
• vinpocetine
• vascular cognitive disturbances
• functional brain state